Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects
Authors:
Open Access
- 1 April 2025
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (3) , 1-18
Abstract
Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome’s set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate release (IR) tablets, modified release (MR) tablets and IR solution. A once daily MR microsphere formulation was developed for pediatric patients. Previously, bioequivalence (BE) between the 10 mg once daily (QD) MR microsphere formulation and 5 mg twice daily (BID) IR solution has been established with PBPK virtual BE trials (VBE) in place of a clinical BE trial in healthy adult population. In this research, the PBPK model based VBE approach was extended to pediatric population. Pediatric PBPK model verification was conducted by first examining predicted vs observed demographic information such as body weight (BWT) and glomerular filtration rate (GFR). After confirming the alignment in demographic background between clinical study participants vs virtual pediatric subjects, multiple ontogeny profiles for CYP3A4 and CYP2C19 were examined. The established model predicted AUC and Cmax within 1.5-fold of observed values for multiple trials, age groups and formulations. Lastly, VBE trials in pediatric subjects were conducted with PBPK model generated pharmacokinetic (PK) parameter values with clinically observed intra-subject coefficient of variation (ICV) in adults. Since ICV in pediatric population is unknown, the sensitivity around ICV was also evaluated to assess the BE risk between IR solution and MR microsphere formulation in pediatric population. The results demonstrated that the IR oral solution BID and MR microsphere formulation QD are BE in pediatric population.Keywords
This publication has 25 references indexed in Scilit:
- Tofacitinib: A Review in Rheumatoid ArthritisDrugs, 2017
- Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in ChildrenClinical Pharmacology & Therapeutics, 2017
- Literature Review of Gastrointestinal Physiology in the Elderly, in Pediatric Patients, and in Patients with Gastrointestinal DiseasesJournal of Pharmaceutical Sciences, 2016
- Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modelingThe Journal of Clinical Pharmacology, 2015
- The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in HumansDrug Metabolism and Disposition, 2014
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and ChildrenClinical Pharmacokinetics, 2006
- Measurement of Gastrointestinal pH and Regional Transit Times in Normal ChildrenJournal of Pediatric Gastroenterology and Nutrition, 1990
- pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry deviceAlimentary Pharmacology & Therapeutics, 1989